A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

Summary

The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders. The safety profile will primarily be assessed by neutrophil engraftment.

Timeline

Start

2015-06

Primary completion

2016-12

Completion

2017-02

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications